Releases Details

MaxCyte, Inc.

("MaxCyte" or the "Company")

Director Dealings and Issue of Equity

Gaithersburg, Maryland - 4 February 2021: MaxCyte (LSE: MXCT, MXCL), the global cell-based medicines and life sciences company, announces that further to the announcement of a £40 million (approx. $55 million) Subscription via a private placement of 5,740,000 new shares of common stock (the "Subscription Announcement") on 3 February, 2021, Doug Doerfler, Chief Executive Officer and a Founder of the Company, Ron Holtz, Senior Vice President and Chief Accounting Officer  and J. Stark Thompson, Non-Executive Chairman, have exercised options in the amount of  755,000 shares of common stock,  $0.01 par, of the Company ("Common Stock") ("Exercise") in aggregate. The 755,000 new shares of Common Stock issued pursuant to the Exercise ("New Options Common Stock") have been sold by Doug Doerfler, Ron Holtz and J. Stark Thompson at a price of 700 pence per Common Stock ("Sale").

Following the Exercise and Sale, Mr Doerfler's holding of Common Stock remains unchanged at a total of 433,197 shares and Mr Holtz's holding of Common Stock remains unchanged at a total of 150,251 shares, representing 0.5% and 0.2%, respectively, of the enlarged issued share capital of the Company following the Subscription and the Exercise. Mr. Doerfler, Mr. Holtz and Dr Thompson hold a further 2,313,480, 1,014,892 and 211,333 options over Common Stock respectively.

Total voting rights

Application has been made for admission of the 755,000 New Options Common Stock to trading on AIM, which is anticipated to occur at 8:00am on 8 February 2021 ("Options Stock Admission"). The New Options Common Stock will rank pari passu with the existing shares of common stock of the Company and will trade in the unrestricted line of Common Stock trading under the symbol MXCT. The total issued stock capital of the Company following the Options Stock Admission and the admission to trading on AIM of the 5,740,000 shares of Subscription Common Stock ("Subscription Stock Admission") will be 83,917,169 shares of common stock. Following Option Stock Admission and Subscription Stock Admission, Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

Following Subscription Stock Admission (which comprises First Admission and Second Admission) and Options Stock Admission, the number of unrestricted shares of Common Stock trading under the symbol 'MXCT' will be 73,687,080; the number of restricted shares of Common Stock trading under the symbol 'MXCL' will be 9,900,089 and the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.

Save as otherwise defined, capitalised terms used in this announcement have the meanings given to them in the Subscription Announcement.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

For the purposes of MAR, the person responsible for arranging for the release of this Announcement on behalf of the Company is Maher Masoud, General Counsel.

For further information, please contact:

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.